Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16176549 | 1.00 | TUBB1 (0.52) | TUBB1CTSLALDH1A1MEN1KMT2A | |
| SCHEMBL19282602 | 1.00 | TUBB1 (0.52) | TUBB1CTSLALDH1A1MEN1KMT2A | |
| SCHEMBL16176544 | 1.00 | TUBB1 (0.52) | TUBB1CTSLALDH1A1MEN1KMT2A | |
| SCHEMBL20723988 | 1.00 | TUBB1 (0.52) | TUBB1CTSLALDH1A1MEN1KMT2A | |
| SCHEMBL16176275 | 0.93 | TUBB1 (0.53) | TUBB1CTSLMEN1KMT2ACTSB | |
| SCHEMBL20723975 | 0.93 | TUBB1 (0.53) | TUBB1CTSLMEN1KMT2ACTSB | |
| SCHEMBL16176274 | 0.93 | TUBB1 (0.53) | TUBB1CTSLMEN1KMT2ACTSB | |
| SCHEMBL16176277 | 0.93 | TUBB1 (0.53) | TUBB1CTSLMEN1KMT2ACTSB | |
| SCHEMBL19282673 | 0.93 | TUBB1 (0.53) | TUBB1CTSLMEN1KMT2ACTSB | |
| SCHEMBL16176313 | 0.92 | TUBB1 (0.58) | TUBB1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-04-04 | — | — | US | disclosed |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| EP-2968440-B1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS INC (CA) | 2019-06-05 | — | — | EP | disclosed |
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2019-02-12 | — | — | US | disclosed |
| US-9522876-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2016-12-20 | — | — | US | disclosed |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-02-11 | — | — | US | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | TUBB1 106/4885CTSL 488/4885ALDH1A1 3393/4885 |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, CCNB2, CCNB3 | TUBB1 236/4885CTSL 378/4885ALDH1A1 2218/4885 |
| US-10201614-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, CCNB2 | TUBB1 107/4885CTSL 513/4885ALDH1A1 3403/4885 |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | TUBB1 106/4885CTSL 488/4885ALDH1A1 3393/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | TUBB1 106/4885CTSL 488/4885ALDH1A1 3393/4885 |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | TUBB1 106/4885CTSL 488/4885ALDH1A1 3393/4885 |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, CCNB2 | TUBB1 107/4885CTSL 513/4885ALDH1A1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.